News summary

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Source: TechCrunch • Published: 17 Nov 2026, 14:50

Summarized by Masters of Longevity from TechCrunch.

Isomorphic Labs raised $5 billion to push AI-designed drug candidates toward clinical trials.

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Key Takeaways
  • Isomorphic Labs showed positive preclinical oncology and immunology results.
  • The funding is meant to scale its AI drug-design engine and programs.
  • Preclinical findings are not proof of safety or human efficacy.
Read the full article at TechCrunch ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?